All In Biotech

NDA 022427 · Abbvie

Acuvail

Ketorolac Tromethamine · Ophthalmic

Last checked: Nov 20, 2026Latest source record: May 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 22, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

238

46 Phase 3, 16 recruiting

FAERS reports

4,504

2,551 serious, 262 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 31, 2024.

ACUVAIL ® is indicated for the treatment of pain and inflammation following cataract surgery. ACUVAIL is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery. ( 1 )

Mechanism: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 22, 2009 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • ACUVAIL · KETOROLAC TROMETHAMINE 0.45% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketorolac Tromethamine" as an intervention, any sponsor and status, largest first.

All 238 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective491
  • drug hypersensitivity301
  • nausea253
  • headache249
  • pain237
  • dyspnoea220
  • fatigue219
  • treatment failure205
  • off label use179
  • vomiting160
  • diarrhoea149
  • eye pain147

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200443
200570
200669
200764
200883
2009106
2010138
2011180
2012195
201378
201484
2015103
2016306
2017232
2018203
2019278
2020459
2021222
2022301
2023365
2024339
2025345
2026241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Acuvail (Ketorolac Tromethamine/PF)

2024 spending

$134K

Beneficiaries

131

263 claims

Per beneficiary

$1,025

$10.81 per unit

View as table
YearSpending
2020$215,551
2021$221,208
2022$145,369
2023$173,941
2024$134,335

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 278 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.